Amgen's osteoporosis drug debuts with $22K annual price tag

Amgen's new osteoporosis drug Evenity will launch at a price of $1,825 per month or $21,900 annually, according to Reuters.

The drug, approved by the FDA last week, is approved to treat osteoporosis in postmenopausal women at high risk of bone fracture. The drug carries a boxed warning, which flags increased risk of heart attack, stroke and cardiovascular-related deaths.

Evenity, part of a new class of drugs known as sclerostin inhibitors, is designed to reduce the risk of fracture by building bone mass and inhibiting the breakdown of bone minerals.

Analysts expect Evenity to pull in revenue of $274 million by 2024.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars